Asston Pharmaceuticals Limited (BOM:544445)
India · Delayed Price · Currency is INR 62.45
-1.79 (-2.79%)
At close: Jul 27, 2026
Asston Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 38.65 | 43.25 | 13.6 | 10.57 | 1.11 |
Depreciation & Amortization | 3.24 | 0.81 | 0.51 | 0.37 | 0.08 |
Loss (Gain) From Sale of Assets | - | -0.56 | - | - | - |
Other Operating Activities | -11.78 | 22.78 | 8.98 | 10.52 | 4.5 |
Change in Accounts Receivable | -120.18 | -83.98 | -75.43 | -22.09 | -21.66 |
Change in Inventory | -0.5 | 7.22 | 0.62 | -9.98 | 7.29 |
Change in Accounts Payable | -3.18 | 0.52 | 2.7 | 10.14 | 1.84 |
Change in Other Net Operating Assets | -8.05 | 8.33 | 11.02 | -2.68 | -5.02 |
Operating Cash Flow | -101.8 | -1.63 | -38 | -3.16 | -11.86 |
Operating Cash Flow Growth | - | - | - | - | - |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -100.63 | - | -0.1 | -2.51 | -0.02 |
Sale of Property, Plant & Equipment | - | 1.11 | - | - | - |
Investment in Securities | - | 7.09 | -0.35 | -6.73 | - |
Other Investing Activities | 1.55 | 0.49 | 0.4 | 0.12 | 0 |
Investing Cash Flow | -99.08 | 8.68 | -0.05 | -9.12 | -0.02 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Short-Term Debt Issued | - | - | 17.66 | 10.57 | 23.69 |
Long-Term Debt Issued | - | 6.3 | - | 8.78 | - |
Total Debt Issued | - | 6.3 | 17.66 | 19.36 | 23.69 |
Short-Term Debt Repaid | - | -1.93 | - | - | - |
Long-Term Debt Repaid | -21.5 | - | -1.92 | - | -13.33 |
Total Debt Repaid | -21.5 | -1.93 | -1.92 | - | -13.33 |
Net Debt Issued (Repaid) | -21.5 | 4.37 | 15.75 | 19.36 | 10.36 |
Issuance of Common Stock | 239.61 | - | 30.46 | - | 6.9 |
Other Financing Activities | -6.33 | -9.5 | -9.33 | -7.21 | -4.34 |
Financing Cash Flow | 211.79 | -5.13 | 36.88 | 12.15 | 12.93 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Miscellaneous Cash Flow Adjustments | - | 0 | - | 0 | 0 |
Net Cash Flow | 10.92 | 1.93 | -1.17 | -0.13 | 1.04 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -202.42 | -1.63 | -38.11 | -5.67 | -11.89 |
Free Cash Flow Growth | - | - | - | - | - |
Free Cash Flow Margin | -79.48% | -0.65% | -24.45% | -8.67% | -12.38% |
Free Cash Flow Per Share | -25.77 | -0.26 | -6.80 | -1.01 | -124.88 |
Levered Free Cash Flow | -257.09 | -18.39 | -57.54 | -18.64 | -9.74 |
Unlevered Free Cash Flow | -253.13 | -13.41 | -51.91 | -14.42 | -7.08 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 6.33 | 9.5 | 9.33 | 7.21 | 4.34 |
Cash Income Tax Paid | 23.82 | -0.03 | 4.52 | 0.13 | 0.32 |
Change in Working Capital | -131.91 | -67.91 | -61.09 | -24.61 | -17.55 |